Tyra Biosciences Inc. (TYRA)
Tyra Biosciences Statistics
Share Statistics
Tyra Biosciences has 50.75M shares outstanding. The number of shares has increased by -3.29% in one year.
| Shares Outstanding | 50.75M |
| Shares Change (YoY) | -3.29% |
| Shares Change (QoQ) | -4.01% |
| Owned by Institutions (%) | 82.57% |
| Shares Floating | 30.76M |
| Failed to Deliver (FTD) Shares | 2.87K |
| FTD / Avg. Volume | 0.92% |
Short Selling Information
The latest short interest is 3.75M, so 7.06% of the outstanding shares have been sold short.
| Short Interest | 3.75M |
| Short % of Shares Out | 7.06% |
| Short % of Float | 12.63% |
| Short Ratio (days to cover) | 16.91 |
Valuation Ratios
The PE ratio is -9.2 and the forward PE ratio is -4.2. Tyra Biosciences's PEG ratio is 1.35.
| PE Ratio | -9.2 |
| Forward PE | -4.2 |
| PS Ratio | 0 |
| Forward PS | 1.8 |
| PB Ratio | 2.32 |
| P/FCF Ratio | -11.29 |
| PEG Ratio | 1.35 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Tyra Biosciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 23.81, with a Debt / Equity ratio of 0.02.
| Current Ratio | 23.81 |
| Quick Ratio | 23.81 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.06 |
| Debt / FCF | -0.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1.44M |
| Employee Count | 60 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -37.31% in the last 52 weeks. The beta is 1.19, so Tyra Biosciences's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -37.31% |
| 50-Day Moving Average | 10.39 |
| 200-Day Moving Average | 16.74 |
| Relative Strength Index (RSI) | 57.45 |
| Average Volume (20 Days) | 313.43K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -104.18M |
| Net Income | -86.48M |
| EBITDA | -104.18M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -1.51 |
Balance Sheet
The company has 91.97M in cash and 6.22M in debt, giving a net cash position of 85.74M.
| Cash & Cash Equivalents | 91.97M |
| Total Debt | 6.22M |
| Net Cash | 85.74M |
| Retained Earnings | -251.31M |
| Total Assets | 363.56M |
| Working Capital | 332.87M |
Cash Flow
In the last 12 months, operating cash flow was -69.77M and capital expenditures -664K, giving a free cash flow of -70.44M.
| Operating Cash Flow | -69.77M |
| Capital Expenditures | -664K |
| Free Cash Flow | -70.44M |
| FCF Per Share | -1.23 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TYRA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for TYRA is $30.5, which is 204.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $30.5 |
| Price Target Difference | 204.1% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 13.32 |
| Piotroski F-Score | 2 |